Bio-Path Holdings, Inc. (NASDAQ:BPTH) shares are trading higher Monday after the company announced the presentation of interim results from its Phase 2 study of prexigebersen (BP1001) in combination with decitabine and venetoclax for the treatment of acute myeloid leukemia (AML).
The Details:
The company presented data on Saturday which showed prexigebersen to be well-tolerated and has demonstrated efficacy results in two reporting cohorts including newly diagnosed AML patients and refractory/relapsed AML patients, both of which exceeded outcomes with frontline therapy.
Related News: What’s Going On With Snowflake Stock?
“We were honored to have our data selected for oral presentation at ASCO as it underscores not only the quality of our data, but also highlights the continued unmet need for these most vulnerable cancer patients,” said Peter Nielsen, CEO of Bio-Path.
“We continue to advance this important study confident that prexigebersen can make ...